Literature DB >> 28710679

New Phage Display-Isolated Heptapeptide Recognizing the Regulatory Carboxy-Terminal Domain of Human Tumour Protein p53.

Sihem Ben Abid1, Mouna Sahnoun2, Ines Yacoubi-Hadj Amor3, Salma Abdelmoula-Souissi1, Hajer Hassairi4, Raja Mokdad-Gargouri1, Ali Gargouri5.   

Abstract

The transcription factor tumor protein p53 (P53) controls a variety of genes most involved in cell cycle and is at the origin of apoptosis when DNA is irreparably damaged. We planned to select novel tumor protein p53-interacting peptides through the screening of hepta-peptide phage-display libraries. For this aim, human tumor suppressor protein p53 was expressed in Escherichia coli as Glutathione S-transferase fusion and purified by affinity chromatography. The phage library was then screened on this immobilized protein target. After three rounds of panning, phages were sequenced and shown to contain a consensus sequence NPNSAQG. Thereafter, either free p53 liberated from the fusion protein through thrombin treatment or Histidine-tagged p53 were recognized efficiently by the selected phage. To locate the p53-binding epitope of the selected hepta-peptide, three long peptides parts of the three known domains of the protein were synthesized and screened by the selected phage/peptide. Thus, the Carboxy-terminal p53 region was shown to be the target of the isolated phage as well as by its derived Fluorescein isothiocyanate-peptide. Molecular docking showed Lysine 386 as an important residue potentially engaged in this interaction. The selected hepta-peptide is a novel p53-interacting peptide, not described by other studies, and could be used as therapeutic tool in the future.

Entities:  

Keywords:  Apoptosis; Phage display; Recombinant protein; Synthetic peptides; Tumor protein P53

Mesh:

Substances:

Year:  2017        PMID: 28710679     DOI: 10.1007/s10930-017-9730-1

Source DB:  PubMed          Journal:  Protein J        ISSN: 1572-3887            Impact factor:   2.371


  31 in total

1.  The C-terminus of p53: the more you learn the less you know.

Authors:  J Ahn; C Prives
Journal:  Nat Struct Biol       Date:  2001-09

2.  p53 linear diffusion along DNA requires its C terminus.

Authors:  Kristine McKinney; Melissa Mattia; Vanesa Gottifredi; Carol Prives
Journal:  Mol Cell       Date:  2004-11-05       Impact factor: 17.970

Review 3.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

Review 4.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

Authors:  A Sigal; V Rotter
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

5.  p53 requires an intact C-terminal domain for DNA binding and transactivation.

Authors:  Hyunjung Kim; Kyunghwan Kim; Jongkyu Choi; Kyu Heo; Hwa Jin Baek; Robert G Roeder; Woojin An
Journal:  J Mol Biol       Date:  2011-12-09       Impact factor: 5.469

Review 6.  The UMD-p53 database: new mutations and analysis tools.

Authors:  Christophe Béroud; Thierry Soussi
Journal:  Hum Mutat       Date:  2003-03       Impact factor: 4.878

7.  Targeting p53 for Novel Anticancer Therapy.

Authors:  Zhen Wang; Yi Sun
Journal:  Transl Oncol       Date:  2010-02       Impact factor: 4.243

Review 8.  MDM2 and MDM4: p53 regulators as targets in anticancer therapy.

Authors:  Franck Toledo; Geoffrey M Wahl
Journal:  Int J Biochem Cell Biol       Date:  2007-04-08       Impact factor: 5.085

9.  3Drefine: an interactive web server for efficient protein structure refinement.

Authors:  Debswapna Bhattacharya; Jackson Nowotny; Renzhi Cao; Jianlin Cheng
Journal:  Nucleic Acids Res       Date:  2016-04-29       Impact factor: 16.971

10.  Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.

Authors:  Perry Tal; Shay Eizenberger; Elad Cohen; Naomi Goldfinger; Shmuel Pietrokovski; Moshe Oren; Varda Rotter
Journal:  Oncotarget       Date:  2016-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.